Allogeneic cell therapy bioprocess economics and optimization: Single-use cell expansion technologies

Biotechnology and Bioengineering

Volumn 111, Issue 1, 2014, Pages 69-83

  Simaria, Ana S ^a   Hassan, Sally ^a   Varadaraju, Hemanthram ^b   Rowley, Jon ^b   Warren, Kim ^b   Vanek, Philip ^b   Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Lonza Walkersville Inc   (United States)

Author keywords

Allogeneic cell therapy manufacture; Bioprocess economics; Cell factories; Microcarriers; Single use cell expansion; Stem cells

Indexed keywords

ALLOGENEIC CELLS; BIOPROCESSES; CELL EXPANSION; ECONOMIC COMPETITIVENESS; MICROCARRIERS; PERFORMANCE CAPABILITY; THERAPEUTIC POTENTIALS; WINDOWS OF OPERATIONS;

BIOREACTORS; COST EFFECTIVENESS; MANUFACTURE; OPTIMIZATION; STEM CELLS; TOOLS;

TECHNOLOGY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BIOPROCESS; BIOREACTOR; CELL EXPANSION; CELL THERAPY; FEMALE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ALGORITHM; ALLOTRANSPLANTATION; BIOLOGICAL THERAPY; BIOTECHNOLOGY; CELL CULTURE TECHNIQUE; CYTOLOGY; DEVICES; ECONOMICS; PROCEDURES; STEM CELL;

ALGORITHMS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL- AND TISSUE-BASED THERAPY; HUMANS; STEM CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84888069210     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25008     Document Type: Article

References (39)

1. Birch JR, Racher AJ. 2006. Antibody production. Adv Drug Deliver Rev 58:671-685.
2. Bowden MJ. 2004. Moore's Law and the technology S-curve. Curr Issues Technol Manage 8(1):1-4.
3. Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley JA. 2011. Cell therapy bioprocessing. BioProcess Int 9(Suppl. 1):30-37.
4. Christ B, Stock P. 2012. Mesenchymal stem cell derived hepatocytes for functional liver replacement. Front Immunol 3(168):1-10.
5. DelaRosa O, Dalemans W, Lombardo E. 2012. Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol 3(182):1-8.
6. Farid SS. 2006. Established bioprocesses for producing antibodies as a basis for future planning. Adv Biochem Eng Biotechnol 101:1-42.
7. Frauenschuh S, Reichmann E, Ibold Y, Goetz PM, Sittinger M, Ringe J. 2007. A microcarrier-based cultivation system for expansion of primary mesenchymal stem cells. Biotechnol Prog 23:187-193.
8. Goldschlager T, Rosenfeld JV, Ghosh P, Itescu S, Blecher C, McLean C, Jenkin G. 2011. Cervical interbody fusion is enhanced by allogeneic mesenchymal precursor cells in an ovine model. SPINE 36:615-623.
9. Griffith LG, Naughton G. 2002. Tissue engineering: Current challenges and expanding opportunities. Science 295:1009-1014.
10. Hambor JE. 2012. Bioreactor design and bioprocess controls for industrialized cell processing: Bioengineering strategies and platform technologies. BioProcess Int 10:22-33.
11. Jung KH, Uhm Y-K, Lim YJ, Yim SV. 2011. Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. Int J Oncol 39:137-143.
12. Kelley B. 2007. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Prog 23:995-1008.
13. Kempken R, Preissmann A, Berthold W. 1995. Assessment of a disc stack centrifuge for use in mammalian cell separation. Biotechnol Bioeng 46:132-138.
14. Kirouac DC, Zandstra PW. 2008. The systematic production of cells for cell therapies. Cell Stem Cell 3:369-381.
15. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. 2009. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 15:804-811.
16. Lapinskas E. 2010. Scaling up research to commercial manufacturing. Chem Eng Prog 106:S44-S55.
17. Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R, Vemuri M, Suuronen R. 2009. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 11:958-972.
18. Lopez F, Di Bartolo C, Piazza T, Passannanti A, Gerlach JC, Gridelli B, Triolo F. 2010. A quality risk management model approach for cell therapy manufacturing. Risk Anal 30:1857-1871.
19. Malik N. 2012. Allogeneic versus autologous stem-cell therapy. BioPharm Int 25:36-40.
20. Mason C, Dunnill P. 2009. Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors. Regen Med 4:153-157.
21. Meyers VM, Zayzafoon M, Douglas JT, McDonald JM. 2005. RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J Bone Miner Res 20:1858-1866.
22. Miljan EA, Sinden JD. 2009. Stem cell treatment of ischemic brain injury. Curr Opin Mol Ther 11:394-403.
23. Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO, Strasser D, Ting AE, Sherman W. 2012. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase I clinical study. Circ Res 110:304-311.
24. Rajala K, Lindroos B, Hussein SM, Lappalainen RS, Pekkanen-Mattila M, Inzunza J, Rozell B, Miettinen S, Narkilahti S, Kerkelä E, Aalto-Setälä K, Otonkoski T, Suuronen R, Hovatta O, Skottman H, 2010. A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS ONE 5:1-14.
25. Ratcliffe E, Thomas RJ, Williams DJ. 2011. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. Br Med Bull 100:135-155.
26. Reinecke H, Minami E, Zhu W-Z, Laflamme MA. 2008. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 103:1058-1071.
27. Rowley J, Abraham E, Campbell A, Brandwein H, Oh S. 2012. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int 10:16-22.
28. Rubin PJ, Bennett JM, Doctor JS, Tebbets BM, Marra KG. 2007. Collagenous microbeads as a scaffold for tissue engineering with adipose-derived stem cells. Plast Reconstr Surg 120:414-424.
29. Sart S, Schneider Y-J, Agathos SN. 2010. Influence of culture parameters on ear mesenchymal stem cells expanded on microcarriers. J Biotechnol 150:149-160.
30. Schilling MA, Esmundo M. 2009. Technology S-curves in renewable energy alternatives: Analysis and implications for industry and government. Energ Policy 37:1767-1781.
31. Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. 2012. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 379:713-720.
32. Smith DM. 2012. Assessing commercial opportunities for autologous and allogeneic cell-based products. Regen Med 7:721-732.
33. Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A, Gage F, Weissman I, Uchida N. 2002. Engraftment of sorted/expanded human central nervous system stem cells from foetal brain. J Neurosci Res 69:976-986.
34. Vaes B, Craeye D, Pinxteren J. 2012. Quality control during manufacture of a stem cell therapeutic. BioProcess Int Suppl Cell Ther Anal 10:50-55.
35. Want AJ, Nienow AW, Hewitt CJ, Coopman K. 2012. Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: Beyond the T flask. Regen Med 7:71-84.
36. Whitford WG, Fairbank A. 2011. Considerations in scale-up of viral vaccine production. BioProcess Int 9:16-28.
37. Wu Q-F, Wu C-T, Dong B, Wang L-S. 2003. Cultivation of human mesenchymal stem cells on macroporous CultiSpher G microcarriers. J Exp Hematol/Chin Assoc Pathophysiol 11:15-21.
38. Yang Y, Rossi FMV, Putnins EE. 2007. Ex vivo expansion of rat bone marrow mesenchymal stromal cells on microcarrier beads in spin culture. Biomaterials 28:3110-3120.
39. Zayzafoon M, Gathings WE, McDonald JM. 2004. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis. Endocrinology 145:2421-2432.